Entero Therapeutics
Entero Therapeutics is a biopharmaceutical company focused on developing therapies for gastrointestinal diseases. Their mission is to develop innovative treatments to improve patient outcomes and quality of life, with ongoing research and clinical programs targeting gastrointestinal and infectious diseases.
Industries
Nr. of Employees
small (1-50)
Entero Therapeutics
Patents
Methods and compositions for treating conditions associated with an abnormal inflammatory response
US-11793777-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10912746-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10905666-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10849867-B2
View Details
Methods and compositions for treating conditions associated with an abnormal inflammatory response
US-11793777-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10912746-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10905666-B2
View DetailsMethods and compositions for treating conditions associated with an abnormal inflammatory response
US-10849867-B2
View DetailsProducts
Oral recombinant lipase formulated for enteric delivery
An orally administered, non-animal recombinant lipase formulated in enteric capsules intended to improve fat digestion and nutrient absorption in patients with exocrine pancreatic insufficiency.
Oral enzyme therapy for gluten peptide degradation
An orally delivered enzyme intended to degrade dietary gluten peptides in the GI tract to reduce antigenic exposure and associated symptoms.
Oral selective small-molecule GI receptor agonist
An orally administered small-molecule program targeting GI-specific receptors to modulate gastrointestinal motility for indications such as gastroparesis.
Oral recombinant lipase formulated for enteric delivery
An orally administered, non-animal recombinant lipase formulated in enteric capsules intended to improve fat digestion and nutrient absorption in patients with exocrine pancreatic insufficiency.
Oral enzyme therapy for gluten peptide degradation
An orally delivered enzyme intended to degrade dietary gluten peptides in the GI tract to reduce antigenic exposure and associated symptoms.
Oral selective small-molecule GI receptor agonist
An orally administered small-molecule program targeting GI-specific receptors to modulate gastrointestinal motility for indications such as gastroparesis.
Services
Planning and operational execution of multi-center Phase 2 clinical trials, including protocol design, site activation, patient enrollment, safety oversight and endpoint management.
Management of clinical drug supply logistics, including selection and management of third‑party packaging and labeling vendors, QP release coordination and distribution to trial sites.
Preparation of regulatory filings and engagement with health authorities to support clinical development strategy, IND submissions and agency meetings.
Planning and operational execution of multi-center Phase 2 clinical trials, including protocol design, site activation, patient enrollment, safety oversight and endpoint management.
Management of clinical drug supply logistics, including selection and management of third‑party packaging and labeling vendors, QP release coordination and distribution to trial sites.
Preparation of regulatory filings and engagement with health authorities to support clinical development strategy, IND submissions and agency meetings.
Expertise Areas
- Clinical trial management for Phase 2 programs
- Recombinant enzyme and non-animal biologics development
- Gastrointestinal therapeutics and GI bioanalytics
- Enteric oral formulation and targeted GI delivery
Key Technologies
- Recombinant enzyme therapeutics
- Enteric / delayed-release oral capsule formulation
- Oral non-systemic biologic delivery
- Selective small-molecule GI receptor agonists
News & Updates
The first two patients have been dosed in Turkey for the Phase 2 trial evaluating MS1819 in combination with PERT for severe exocrine pancreatic insufficiency in cystic fibrosis patients.
AzurRx raised gross proceeds of $15.2 million from a private placement and exchanged $6.9 million of promissory notes into the private placement, strengthening its balance sheet.
AzurRx received over 1 million Euros in 2018 CIR, a French R&D tax credit supporting its research activities.
AzurRx discusses issues with porcine ingredients in pharmaceuticals and their efforts to develop synthetic alternatives, including their lead product candidate MS1819.
AzurRx announced statistically significant improvement in CFA in a Phase IIa trial of MS1819-SD for exocrine pancreatic insufficiency caused by chronic pancreatitis.
The first two patients have been dosed in Turkey for the Phase 2 trial evaluating MS1819 in combination with PERT for severe exocrine pancreatic insufficiency in cystic fibrosis patients.
AzurRx raised gross proceeds of $15.2 million from a private placement and exchanged $6.9 million of promissory notes into the private placement, strengthening its balance sheet.
AzurRx received over 1 million Euros in 2018 CIR, a French R&D tax credit supporting its research activities.
AzurRx discusses issues with porcine ingredients in pharmaceuticals and their efforts to develop synthetic alternatives, including their lead product candidate MS1819.
AzurRx announced statistically significant improvement in CFA in a Phase IIa trial of MS1819-SD for exocrine pancreatic insufficiency caused by chronic pancreatitis.